The most important fact in Persistent Systems vs Mphasis is easy to miss:

The revenue bases are almost identical.

That makes denominator excuses much less useful than in comparisons between Persistent and mega-cap IT companies.

Persistent is not growing faster simply because it is one-tenth the size of the competitor.

Against Mphasis, the denominator is essentially comparable.

For Bull Run's related research, see Persistent Systems, Mphasis, How to Analyse IT Services Stocks, HCLTech vs Persistent Systems and Persistent Systems vs Coforge.

Q1 FY27 comparison

This is a rare near-equal-scale growth test

This does not mean Persistent is automatically the better stock.

It means its current operating performance is stronger.

Valuation is a separate question.

Persistent's 25-quarter streak reinforces the evidence

Q1 FY27 marked Persistent's 25th consecutive quarter of sequential revenue growth.

That is more than six years of uninterrupted quarterly expansion.

Its latest Q1 growth was:

• 3.8% QoQ in reported dollars,
• 4.1% QoQ in constant currency,
• 16.1% YoY in reported dollars,
• 16.5% YoY in constant currency.

The growth record is therefore both long and current.

Mphasis is also accelerating, just from a slower trajectory

Mphasis reported:

• 8.3% YoY CC growth,
• 2.1% QoQ CC growth,
• 9.9% YoY CC growth in Direct revenue,
• 2.2% QoQ Direct CC growth.

Those are healthy numbers.

Mphasis is not a low-growth IT company today.

It simply trails an unusually strong Persistent growth rate.

Mphasis expects Q2 to improve further

Management has indicated that Q2 FY27 could deliver its strongest sequential constant-currency growth in roughly three years.

It retained FY27 growth guidance of:

high-single-digit to low-double-digit CC growth.

That means the current 8.3% YoY result sits inside a broader acceleration plan rather than representing the peak target.

Margin is where Persistent currently separates itself

Persistent generated an EBIT margin of 16.0%.

EBIT grew 32.7% YoY.

Mphasis generated an EBIT margin around 14.8%, down roughly 60 bps sequentially.

Mphasis management cited:

• large-deal ramp-up expense,
• capacity investments,
• lower utilisation,
• acquisition-related costs.

Mphasis's margin pressure may be intentionally temporary

A company preparing for large deal ramps often hires or reserves delivery capacity before revenue appears.

That depresses utilisation today.

If the deals ramp as expected:

• revenue rises,
• bench employees become billable,
• utilisation recovers,
• margin improves.

The risk is that the expected revenue arrives later or at lower profitability.

Mphasis maintained its margin guidance

The FY27 operating-margin range remains approximately:

14.75% to 15.75%.

Q1 at roughly 14.8% was near the bottom of that band.

Management therefore expects some recovery through the year if growth and utilisation improve.

BFSI concentration is the largest structural difference

Persistent is almost perfectly split across three large vertical groups.

Mphasis is far more financially concentrated.

Persistent BFSI is growing without dominating the company

Persistent's Q1 BFSI business represented about 34% of revenue and grew approximately 16.3% YoY in dollar terms under company reporting.

The company remains exposed to financial-services technology spending without making its entire consolidated growth dependent on BFSI.

Healthcare contributed 25.3%.

Software, Hi-Tech and Emerging Industries contributed 40.7%.

Mphasis has much deeper BFS and Insurance exposure

Mphasis reported approximately:

• ₹2,355 crore BFS revenue,
• ₹666 crore Insurance revenue.

Against ₹4,384 crore of consolidated Q1 revenue, the combined analytical share is roughly 69%.

This creates both:

• specialist expertise,
• concentration risk.

Mphasis's specialist model is currently working

Direct BFS grew:

9.4% YoY CC.

Insurance grew:

17.8% YoY CC.

Management has highlighted an eight-quarter compound quarterly BFS growth rate above 3.5%.

That level of repeatability suggests domain expertise is generating wallet-share gains.

Geographic risk moves in the opposite direction

Persistent is diversified by industry but concentrated geographically.

North America represented approximately 79.1% of Q1 revenue.

Europe represented only 8.5%.

This is one reason the proposed Nagarro transaction is strategically important.

Nagarro could reduce Persistent's geographic concentration

Persistent is pursuing a business combination with Frankfurt-listed Nagarro.

The transaction could materially increase:

• European exposure,
• digital-engineering scale,
• AI capabilities,
• industry coverage.

But the transaction remains incomplete as of September 1, 2026.

No Nagarro revenue or earnings belong in Persistent's Q1 numbers.

The acquisition adds financing risk to Persistent

Recent market reporting indicates Persistent expects bridge financing around $1.6 billion for the proposed transaction structure.

If completed, future earnings will need to absorb:

• interest expense,
• integration costs,
• transaction costs,
• potential margin dilution.

Persistent's current standalone balance sheet remains strong, but the future combined structure may look different.

Mphasis has smaller acquisition complexity today

Mphasis has made targeted capability acquisitions, including Theory and Practice / Continuum AI-related assets.

Those deals influenced Q1 costs.

But they are not comparable in scale with the proposed Nagarro transaction.

This gives Mphasis lower transformational integration risk today.

Persistent's Q1 TCV headline needs major normalisation

Persistent reported:

$1.1462 billion of Q1 TCV.

That looks more than twice Mphasis's $461 million.

But one strategic agreement exceeded:

$650 million over 6.5 years.

At least 56.7% of Persistent TCV came from one deal

The simple minimum calculation is:

$650 million ÷ $1.1462 billion ≈ 56.7%.

Because the contract is worth more than $650 million, the true concentration is slightly higher.

The contract is an impressive competitive win.

It should not be interpreted as a normal quarterly booking run-rate.

Persistent ACV provides a better second lens

Annual Contract Value was approximately:

$536.8 million.

That is much closer to Mphasis's $461-million quarterly net-new TCV.

The definitions remain different, but the comparison demonstrates how contract duration can inflate TCV.

Mphasis has the cleaner recent booking consistency

Mphasis's $461-million Q1 net-new TCV marked:

the fifth consecutive quarter above $400 million.

It also included:

• three large deals,
• one $100-million-plus contract,
• trailing-12-month TCV above $1.8 billion.

This is a repeatability signal rather than a one-quarter spike.

Persistent still has the stronger long-term revenue conversion record

Bookings only matter if they become revenue.

Persistent's 25 consecutive sequential growth quarters demonstrate that its historical commercial engine has converted consistently.

Mphasis has also improved conversion, but its long unbroken growth streak is not as strong.

AI is visible differently in the two companies

Mphasis says approximately:

• 63% of Q1 net-new TCV was AI-led,
• 70% of pipeline was AI-led.

Persistent describes AI as embedded across its digital-engineering strategy rather than disclosing one directly comparable percentage of TCV or revenue.

Mphasis has the clearer AI-sales funnel statistic

The 63% figure means nearly two-thirds of Q1 signed net-new contract value included AI-led propositions under Mphasis's classification.

This provides evidence that AI has moved beyond pilot programmes into large commercial engagements.

Persistent's AI strength is visible in engineering execution

Persistent's Q1 wins included:

• AI-led SaaS product development,
• cloud and engineering transformation,
• AI-ready healthcare data platforms,
• enterprise AI production infrastructure.

Its operating growth suggests those capabilities are already contributing materially even without a standalone AI-revenue percentage.

Valuation is where Mphasis becomes much more competitive

Persistent therefore trades at roughly a 77% P/E premium to Mphasis.

Its P/B multiple is more than twice as high.

Persistent's premium is supported by superior returns

Fresh August valuation data showed approximately:

• Persistent ROE: 25.2%,
• Persistent ROIC: 29.8%,
• Mphasis ROE: about 17.7–18.3% depending data date,
• Mphasis ROIC around 17.6–19.6% depending period definition.

Persistent earns substantially more on each rupee of shareholder capital today.

That justifies a premium.

It does not automatically justify any premium.

The market is pricing Persistent for sustained exceptional growth

At more than 43x trailing earnings, Persistent needs:

• continued double-digit organic growth,
• margin resilience,
• successful mega-deal delivery,
• strong Nagarro execution if completed,
• high return ratios.

A slowdown toward Mphasis-like growth without multiple compression through earnings would create valuation risk.

Mphasis has a lower growth hurdle

At roughly 24.5x earnings, Mphasis can justify its valuation with:

• high-single-digit to low-double-digit growth,
• margin recovery toward 15%+,
• continued $400M+ TCV quarters,
• strong AI-led pipeline conversion.

The market requires less perfection.

Bull Run market snapshot

Why Persistent P/E differs between August 25 and August 31

Bull Run's August 25 internal snapshot shows Persistent at 55.6x earnings.

Fresh same-provider BSE data for August 31 shows approximately 43.42x.

The difference reflects updated trailing earnings and provider methodology rather than a 22% collapse in business quality over six days.

Dates are therefore labelled explicitly.

Which has better growth?

Persistent by a wide margin.

16.5% YoY CC versus Mphasis at 8.3%.

Which has stronger sequential momentum?

Persistent.

4.1% QoQ CC versus Mphasis at 2.1%.

Which has the higher EBIT margin?

Persistent.

16.0% versus Mphasis around 14.8%.

Which has better growth quality?

Persistent currently.

It combines faster growth, a higher margin and 25 consecutive sequential-growth quarters at roughly the same revenue scale as Mphasis.

Which has lower industry concentration?

Persistent.

Its three major vertical groups are approximately 41%, 34% and 25%, while Mphasis has roughly 69% broad BFS + Insurance exposure analytically.

Which has greater BFSI expertise?

Mphasis has the more concentrated financial-services identity.

Its financial-services exposure is a core competitive specialisation.

Which has the larger headline TCV?

Persistent.

$1.146 billion versus Mphasis at $461 million.

Which has the cleaner normalised booking comparison?

The gap is much smaller after Persistent's mega deal is considered.

Persistent ACV was $536.8 million, while Mphasis reported $461 million of net-new TCV.

The methodologies remain different.

Which has more consistent recent booking cadence?

Mphasis has a strong claim.

Q1 marked its fifth consecutive quarter above $400 million of net-new TCV.

Which has the clearer AI-led booking statistic?

Mphasis.

63% of Q1 TCV was AI-led.

Which has the stronger long-term operating-growth record?

Persistent.

Twenty-five consecutive sequential growth quarters is the stronger realised execution record.

Which is cheaper?

Mphasis by a wide margin.

Approximately 24.5x trailing earnings versus Persistent at 43.42x on August 31.

Persistent Systems vs Mphasis: category-by-category

Which is stronger in 2026?

Persistent Systems is currently the stronger operating company.

At almost the same quarterly revenue scale as Mphasis, it produces:

• roughly twice the CC growth rate,
• higher EBIT margin,
• stronger return ratios,
• a 25-quarter sequential-growth record,
• better industry diversification.

Mphasis has the stronger valuation setup.

It offers:

• healthy 8.3% CC growth,
• 9.9% Direct growth,
• five consecutive $400M+ TCV quarters,
• 63% AI-led Q1 bookings,
• a P/E roughly 44% below Persistent's August 31 multiple.

The central trade-off is:

Persistent = higher-quality growth with higher returns and a much higher valuation.

Mphasis = cheaper BFSI specialist with credible AI-led acceleration but more concentration and lower current margin.

What to monitor next

• Persistent sequential growth: extension of the 25-quarter streak remains important.
• Persistent EBIT margin: salary hikes and acquisition preparation could create pressure.
• Persistent BFSI: watch whether its 34% mix grows without creating excessive concentration.
• Persistent mega-deal ramp: $650M+ should convert gradually across 6.5 years.
• Nagarro transaction: financing and integration can materially change the risk profile.
• Mphasis Q2 CC growth: management expects the strongest sequential growth in about three years.
• Mphasis margin: utilisation recovery should move EBIT away from the bottom of guidance.
• Mphasis BFS and Insurance: these remain the central growth engines.
• Mphasis AI-led TCV: 63% should translate into actual revenue.
• Mphasis pipeline: approximately 70% AI-led pipeline is a key forward indicator.

Frequently asked questions